TABLE 2.
Treatment-related treatment-emergent AEs by preferred term in ≥1 patient, any grade and grade 3
| AE, n (%) | Grades 1–3a | Grade 3 |
|---|---|---|
| TPST-1120 Monotherapy (n = 20) | ||
| Patients with ≥1 TRAE | 10 (50.0) | 1 (5.0) |
| Nausea | 4 (20.0) | — |
| Fatigue | 3 (15.0) | — |
| Diarrhea | 2 (10.0) | — |
| Hypertension | 1 (5.0) | 1 (5.0) |
| TPST-1120 + Nivolumab (n = 18) | ||
| Patients with ≥1 TRAEb | 14 (77.8) | 3 (16.7) |
| Fatigue | 6 (33.3) | — |
| Diarrhea | 4 (22.2) | — |
| Nausea | 3 (16.7) | — |
| Abdominal pain | 2 (11.1) | — |
| Arthralgia | 1 (5.6) | 1 (5.6) |
| Hepatic enzyme increased | 1 (5.6) | 1 (5.6) |
| Muscle spasms | 1 (5.6) | 1 (5.6) |
aNo grade 4 or 5 TRAEs.
bRelated to either TPST-1120 or nivolumab.